Results 121 to 130 of about 19,553 (185)

Antagonist nanobodies prevent protease inhibition by CD109. [PDF]

J Biol Chem
Jensen KT, Almeida AV, Rönning S, Karlander M, Nielsen NS, Thøgersen IB, Malm M, Andersen GR, Enghild JJ, Rockberg J, Harwood SL.   +10 more
europepmc   +1 more source

Research progress on the application of nanobodies in immunity and infectious skin diseases. [PDF]

Front Immunol
Qiu L, Hu F, Tao X.
europepmc   +1 more source

NanoBondy Reaction through NeissLock Anhydride Allows Covalent Immune Cell Decoration. [PDF]

Bioconjug Chem
Vankayala LR, Adoni KR, Lim SYT, Dam T, Dushek O, Thalassinos K, Howarth MR.   +6 more
europepmc   +1 more source

Pair correlation analysis of Fixed Photoactivatable Localization Microscopy (PALM) and Powerspectral Analysis of Live PALM applied on the Water Channel Aquaporin-3 [PDF]

, 2016
Andersen, I. T., Arnspang, E. C., Hahn, U., Jensen, Ellen Birgitte Agerbo, Jensen, H. H., Lippincott-Schwartz, J., Mortensen, K., Nejsum, L. N., Sengupta, P.   +8 more
core   +1 more source

High-Resolution Quantification of Two-Way Nanobody Synergy Using Automated Liquid Handling and Computational Modeling. [PDF]

Bio Protoc
Bourgeois NM, Bell SW, Olivier JP, Rout MP, Aitchison JD, Mast FD.   +5 more
europepmc   +1 more source

TR-FRET between engineered nanobodies reveals the existence of endogenous CXCR4 oligomers. [PDF]

Commun Biol
Heuninck J, Bobkov V, Grison CM, Fumagalli A, Lescuyer M, Otun O, Bechara C, Lamarque L, Trinquet E, Bachelerie F, Marin P, Mouillac B, Granier S, van der Woning B, de Haard H, Smit MJ, Heukers R, Durroux T.   +17 more
europepmc   +1 more source

Structural mechanisms and insights on multiple nanobodies binding diverse SOD1 epitopes. [PDF]

Commun Biol
Cheng S, Zhong C, Zhu H, Mu K, Jiang H, Zhong P, Ma Z, Liu X, Wang Z, Liu R, Ding Y.   +10 more
europepmc   +1 more source

Crystal structure and nanobodies against domain 3 of the malaria parasite fusogen Plasmodium falciparum HAP2. [PDF]

Biochem J
Lyons FMT, Chmielewski J, Chan LJ, Gabriela M, Chan RWB, Adair A, Tong J, Pymm P, Zeglinski K, Gouil Q, Tham WH, Dietrich MH.   +11 more
europepmc   +1 more source

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections. [PDF]

PLoS Pathog
Bu F, Ye G, Morsheimer K, Turner-Hubbard H, Eaton B, Anantpadma M, Bheemanapally K, Tan C, Davey R, Li F.   +9 more
europepmc   +1 more source

Susceptibility of broad reactivity nanobodies to resistance mutations in the S2 domain of SARS-CoV-2 predicted by yeast display deep mutational scanning. [PDF]

Front Immunol
Ball CR, Ramage W, Mate R, Hufton SE.
europepmc   +1 more source